Literature DB >> 11427427

Antenatal screening for hepatitis B and antibodies to Toxoplasma gondii and rubella virus: evaluation of two commercial immunoassay systems.

R J Diepersloot1, H Dunnewold-Hoekstra, J Kruit-Den Hollander, F Vlaspolder.   

Abstract

A comparative evaluation of the Abbott AxSYM and DPC Immulite random-access analyzers was performed using 497 prospectively collected serum samples. These samples were sent to the laboratory for routine antenatal screening for hepatitis B surface antigen and immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii and rubella virus. The overall agreement between the two assay systems ranged from 97.4 to 100%. After discrepancy analysis, the outcome in terms of sensitivity and specificity varied from 98.2 to 100% for all but one of the assays tested. The AxSYM rubella virus IgG assay tended to report protective or indeterminate antibody levels in 1% of the samples. This shortcoming might be overcome by raising the cutoff of the microparticle enzyme immunoassay system.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11427427      PMCID： PMC96143          DOI： 10.1128/CDLI.8.4.785-787.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  11 in total

1.  Automated rubella antibody screening:a cautionary tale.

Authors:  S O'Shea; H Dunn; S Palmer; J E Banatvala; J M Best
Journal:  J Med Microbiol       Date:  1999-11       Impact factor: 2.472

2.  Surveillance of congenital rubella in Great Britain, 1971-96.

Authors:  P A Tookey; C S Peckham
Journal:  BMJ       Date:  1999-03-20

3.  Determination of anti-Toxoplasma gondii immunoglobulin G avidity: adaptation to the Vidas system (bioMérieux).

Authors:  H Pelloux; E Brun; G Vernet; S Marcillat; M Jolivet; D Guergour; H Fricker-Hidalgo; A Goullier-Fleuret; P Ambroise-Thomas
Journal:  Diagn Microbiol Infect Dis       Date:  1998-10       Impact factor: 2.803

Review 4.  Surveillance of hepatitis B: an example of a vaccine preventable disease.

Authors:  M E Ramsay; A A Rushdy; H E Harris
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

5.  The Abbott IMx automated benchtop immunochemistry analyzer system.

Authors:  M Fiore; J Mitchell; T Doan; R Nelson; G Winter; C Grandone; K Zeng; R Haraden; J Smith; K Harris
Journal:  Clin Chem       Date:  1988-09       Impact factor: 8.327

6.  Comparison of four enzyme immunoassays for detection of immunoglobulin M antibodies against rubella virus.

Authors:  L Matter; M Gorgievski-Hrisoho; D Germann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

7.  Studies of the natural history and prevention of rubella.

Authors:  R H Green; M R Balsamo; J P Giles; S Krugman; G S Mirick
Journal:  Am J Dis Child       Date:  1965-10

Review 8.  Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy.

Authors:  R E McCabe; R G Brooks; R F Dorfman; J S Remington
Journal:  Rev Infect Dis       Date:  1987 Jul-Aug

9.  The significance of specific IgM antibody in the diagnosis of rubella employing the immunofluorescence technique.

Authors:  S Iwakata; A J Rhodes; N A Labzoffsky
Journal:  Can Med Assoc J       Date:  1972-02-19       Impact factor: 8.262

10.  The program for antenatal screening of toxoplasmosis in Finland: a prospective cohort study.

Authors:  M Koskiniemi; M Lappalainen; P Koskela; K Hedman; P Ammälä; V Hiilesmaa; K Teramo
Journal:  Scand J Infect Dis Suppl       Date:  1992
View more
  9 in total

1.  Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies.

Authors:  Wayne Dimech; Lena Panagiotopoulos; Joan Marler; Nicolas Laven; Susan Leeson; Elizabeth M Dax
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  European multicenter study of the LIAISON automated diagnostic system for determination of Toxoplasma gondii-specific immunoglobulin G (IgG) and IgM and the IgG avidity index.

Authors:  Eskild Petersen; Maria Victoria Borobio; Edward Guy; Oliver Liesenfeld; Valeria Meroni; Anne Naessens; Emma Spranzi; Philippe Thulliez
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Evaluation of Toxoplasma gondii immunoglobulin G (IgG) and IgM assays incorporating the newVidia analyzer system.

Authors:  Adriana Calderaro; Giovanna Piccolo; Simona Peruzzi; Chiara Gorrini; Carlo Chezzi; Giuseppe Dettori
Journal:  Clin Vaccine Immunol       Date:  2008-05-14

4.  Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter.

Authors:  Wayne Dimech; Lena Panagiotopoulos; Barbara Francis; Nicholas Laven; Joan Marler; David Dickeson; Tony Panayotou; Kim Wilson; Robyn Wootten; Elizabeth M Dax
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

5.  Evaluation of rubella virus immunoglobulin G (IgG) and IgM assays with the new Vidia instrument.

Authors:  Maria Cristina Medici; Monica Martinelli; Valeria Albonetti; Carlo Chezzi; Giuseppe Dettori
Journal:  J Clin Microbiol       Date:  2008-03-26       Impact factor: 5.948

6.  Help in the Choice of Automated or Semiautomated Immunoassays for Serological Diagnosis of Toxoplasmosis: Evaluation of Nine Immunoassays by the French National Reference Center for Toxoplasmosis.

Authors:  O Villard; B Cimon; C L'Ollivier; H Fricker-Hidalgo; N Godineau; S Houze; L Paris; H Pelloux; I Villena; E Candolfi
Journal:  J Clin Microbiol       Date:  2016-10-12       Impact factor: 5.948

7.  Performance characteristics of current-generation Immulite 2000 TORCH Assays.

Authors:  A R Centonze; E Tonolli; R Fontana
Journal:  Clin Vaccine Immunol       Date:  2012-11-21

8.  Investigation into low-level anti-rubella virus IgG results reported by commercial immunoassays.

Authors:  Wayne Dimech; Nilukshi Arachchi; Jingjing Cai; Terri Sahin; Kim Wilson
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

9.  Collection tubes with or without gel separator did not interfere with detection of rubella virus antibodies IgM and IgG.

Authors:  L C Oliveira; K H Kawasato; M S Otta; L P Lima; T S Okay
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.